Based on the aggregated intelligence of 150,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug specialist Teva Pharmaceutical Industries (Nasdaq: TEVA) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Teva's business and see what CAPS investors are saying about the stock right now.

Teva facts

Headquarters (Founded)

Petach Tikva, Israel (1901)

Market Cap

$54.8 billion



Trailing-12-Month Revenue

$13.9 billion


CEO Shlomo Yanai (since 2007)

CFO Eyal Desheh (since 2008)

Compound Annual Revenue and Net Income Growth (Over Past 5 Years)

23.7% and 43.2%


$2.25 billion / $5.61 billion

Dividend Yield



Watson Pharmaceuticals (NYSE: WPI)

Novartis (NYSE: NVS)

Mylan (Nasdaq: MYL)

Other Highly Rated Pharmaceutical Stocks

Pfizer (NYSE: PFE)

Merck (NYSE: MRK)

Bristol-Myers Squibb (NYSE: BMY)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 96% of the 1,600 members who have rated Teva believe the stock will outperform the S&P 500 going forward. These bulls include mitleg and dhd1491,who is ranked in the top 5% of our community.

Late last year, mitleg made a rather generic case for the stock: "The leader in generic drugs. Well run. Explosive growth. Worldwide the rise in health care costs especially generics will ensure a market for years to come."

In a pitch a few months earlier, dhd1491 elaborated on that bullish line of reasoning:

Aging of developed nations' population will drive demand for pharmaceuticals in general for the remainder of our lives (anyone reading this). Generics, in particular, will benefit from the current effort to rein in escalating health costs. Teva, the largest generic-maker in the world, is right in the sweet spot for top line growth. ... Current market angst over loss of Copaxone patent and worry about indigestion from Barr acquisition are holding the lid on this stock.

What do you think about Teva, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Novartis is a Motley Fool Global Gains pick. Pfizer is an Inside Value selection. The Fool's disclosure policy always gets a perfect score.